


REIVINDICACIONES

1. Un compuesto con la fórmula (0):



o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopos de estos, en el que:

R^1 es alquilo de C_{1-12} , sustituido o no sustituido;

R^2 es haloalquilo C_{1-12} sustituido o no sustituido; heterociclilo- C_{1-12} -alquilo de 3 a 13 miembros sustituido o no sustituido; o carbociclilo- C_{1-12} -alquilo de 3 a 13 miembros sustituido o no sustituido;

R^3 es hidrógeno, halógeno, alquilo de C_{1-6} , sustituido o no sustituido, $-COOR^a$, $-COR^a$, $-CN$, o $-(C=O)N(R^a)_2$;

cada instancia de R^a es independientemente hidrógeno, alquilo de C_{1-6} , sustituido o no sustituido, un grupo protector de oxígeno cuando está unido a un átomo de oxígeno, o un grupo protector de nitrógeno cuando está unido a un átomo de nitrógeno;

cada instancia de R^4 es independientemente hidrógeno, halógeno, alquilo de C_{1-6} , sustituido o no sustituido, $-OR^a$, $-COOR^a$, $-COR^a$, $-N(R^a)_2$, $-CN$, o $-(C=O)N(R^a)_2$;

cada instancia de R^5 es independientemente hidrógeno, halógeno, alquilo de C_{1-6} , sustituido o no sustituido, $-OR^a$, $-COOR^a$, $-COR^a$, $-N(R^a)_2$, $-CN$, o $-(C=O)N(R^a)_2$;

R^6 es hidrógeno, alquilo de C_{1-6} , sustituido o no sustituido, o un grupo protector de nitrógeno;

cada instancia de R^8 es independientemente hidrógeno, halógeno, alquilo de C_{1-6} , sustituido o no sustituido;

cada instancia de R^9 es independientemente hidrógeno, halógeno, alquilo de C_{1-6} , sustituido o no sustituido, $-OR^a$, $-COOR^a$, $-COR^a$, $-N(R^a)_2$, $-CN$, o $-(C=O)N(R^a)_2$, o dos instancias de R^9 se unen para formar un heterociclilo de 3 a 13 miembros, heterociclilo de 3 a 13 miembros, un anillo arilo de 6 a 12 miembros o un anillo heteroarilo de 5 a 14 miembros;

n es un número entero de entre 0 y 4, inclusive;

m es 0, inclusive;


p es un número entero de entre 0 y 3, inclusive;

q es un número entero de entre 0 y 1; y

cuando R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 , y R^9 están sustituidos, cada sustituyente se selecciona independientemente entre halógeno, alquilo C_{1-6} , alcoxi C_{1-6} , alquilo C_{1-6} parcial o totalmente halogenado, $-CN$, $-NO_2$, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-NR^a(C=O)OR^a$, $-COOR^a$, and $-COR^a$.


2. El compuesto de la Reivindicación 1, en el que:

(a) el compuesto tiene la fórmula (0a):




o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopo de estos;

(b) el compuesto tiene la fórmula (0b):



o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopo de estos; o

(c) el compuesto tiene la fórmula (0c):




o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopo de estos.

3. El compuesto de la Reivindicación 1 o 2, en el que q es 1.

4. El compuesto de cualquiera de las Reivindicaciones 1-3, en el que dos instancias de R^9 se unen para formar un anillo de heteroarilo de 5 miembros o un anillo de heterociclilo de 5 miembros.


5. El compuesto de la Reivindicación 1, en donde el compuesto es de fórmula (I):



o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopos de estos, en el que:

cada instancia de R^9 es independientemente hidrógeno, halógeno, alquilo de C_{1-6} , sustituido o no sustituido, $-OR^a$, $-COOR^a$, $-COR^a$, $-N(R^a)_2$, $-CN$, o $-(C=O)N(R^a)_2$.

6. El compuesto de la Reivindicación 1 o 5, en el que el compuesto tiene la fórmula (Iz):



o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopos de estos.

7. El compuesto de cualquiera de las Reivindicaciones 1 y 5-6, en el que n es 1.

8. El compuesto de cualquiera de las Reivindicaciones 1-7, en el que cada R^9 es independientemente hidrógeno, metilo sustituido o no sustituido, cloro, fluoro, metoxi, o $-NH_2$.

9. El compuesto de cualquiera de las Reivindicaciones 1-8, en el que cada R^9 es independientemente metilo sustituido o no sustituido, cloro, fluoro, metoxi o $-NH_2$.


10. El compuesto de cualquiera de las Reivindicaciones 1-9, en el que R^3 es hidrógeno, metilo sustituido o no sustituido, fluoro, cloro, $-CN$, o $-COOR^a$.


11. El Compuesto de cualquiera de las Reivindicaciones 1-10, en el que R^3 es $-CN$, o $-COOR^a$ o cloro.

12. El compuesto de cualquiera de las Reivindicaciones 1-11, en el que R^1 es alquilo de C_{1-3} , sustituido o no sustituido.

13. El compuesto de cualquiera de las Reivindicaciones 1-11, en el que R¹ es metilo o etilo.
14. El compuesto de cualquiera de las Reivindicaciones 1 a 13, en donde R² es haloalquilo C₁₋₆ sustituido o no sustituido.
15. El compuesto de cualquiera de las Reivindicaciones 1 a 13, en donde R² es heterociclil-C₁₋₆-alquilo de 3 a 6 miembros sustituido o no sustituido, o carbociclil-C₁₋₆-alquilo de 3 a 6 miembros sustituido o no sustituido.
16. El compuesto de cualquiera de las Reivindicaciones 1 a 13, en donde R² es carbociclil-C₁₋₆-alquilo de 3 a 6 miembros sustituido o no sustituido, o haloalquilo C₁₋₆ sustituido o no sustituido.
17. El compuesto de cualquiera de las Reivindicaciones 1-13, en el que R² es carbociclil-C₁₋₂-alquilo de 3 a 6 miembros no sustituido, o haloalquilo C₁₋₆ no sustituido.
18. El compuesto de cualquiera de las Reivindicaciones 1-11, en el que R² es ciclopropilmetilo o 2,2-difluoroetilo.
19. El compuesto de la Reivindicación 1, en el que el compuesto se selecciona del grupo que consiste en:


(a)







punto de vista farmacéutico, hidratos, polimorfos, cocristales, tautómeros, estereoisómeros o derivados marcados con isótopos de estos;

(b)







I-631,




I-639,




I-658,




I-677,




I-685,




I-689,




I-690,




I-T2106,




I-T2107,




I-T2120,




I-696,




I-T2162,




I-T2163,




I-697,




I-T2165,




I-T2166,




I-T2167,




I-T2168,




I-T2169,




I-T2170,




I-T2171,




I-T2172,




I-T2174,




I-T2175,




I-T2176,




I-T2177,




I-T2178,

















I-T2179,




I-T2180,




I-T2181,







I-T2223,




I-T2224,




I-T2225,




I-T2241,




I-T2242,




I-T2243,




I-T2244,




I-T2245,




I-T2246,




I-T2247,




I-T2248,




I-T2249,




I-T2250,




I-T2251,




I-T2252,




I-T2253,




I-T2254,




I-T2255,



I-T2256,




I-T2257,




I-T2258, y sales aceptables desde un punto de vista farmacéutico, hidratos, polimorfos, cocristales, tautómeros, estereoisómeros o derivados marcados con isótopos de estos;


(c)




I-674,




I-676,




I-679,




I-681,




I-683,




I-684,




I-687,




I-T2101,




I-T2102,




I-T2109,




I-T2135,




I-T2136,




I-693,




I-T2157,




I-T2158,




I-T2159,




I-T2160,




I-T2173,




I-T2189,




I-T2190,




I-T2191,




I-T2192,




I-T2193,




I-T2194,




I-T2195,




I-T2196,




I-T2197,




I-T2198,




I-T2199,




I-T2200,




I-T2208,




I-T2209,




I-T2210,




I-T2214,




I-T2215,




I-T2216,




I-T2220,




I-T2221,




I-T2222,




I-T2226,




I-T2227,




I-T2228,




I-698,




I-T2230,




I-T2231,




I-T2232,




I-T2233,




I-T2234,




I-




I-T2236,




I-T2237,



I-T2238,




I-T2239,




I-T2240, y sales aceptables

desde un punto de vista farmacéutico, hidratos, polimorfos, cocristales, tautómeros, estereoisómeros o derivados marcados con isótopos de estos.















(d)




I-412,




I-453,







I-689,



I-690,




I-696,




I-697, y sales

aceptables desde un punto de vista farmacéutico, hidratos, polimorfos, cocristales, tautómeros, estereoisómeros o derivados marcados con isótopos de estos.


20. El compuesto de la Reivindicación 1, en donde el compuesto se selecciona del grupo que consiste en:




I-602,




I-619,




I-685,




I-689,




I-696,




I-697,




21. El compuesto de la Reivindicación 1, compuesto seleccionado del grupo que consiste en:







I-696,




I-697,




I-T2251,



I-T2256,




I-T2244,




I-T2253 y sales aceptables desde un punto de vista

farmacéutico, hidratos, polimorfos, cocristales, tautómeros, estereoisómeros o derivados marcados con isótopos de estos.


22. Un compuesto seleccionado del grupo que consiste en:




,




,




,




,






,




,







I-466,




I-467,




I-468,




I-483,




I-484,




I-486,




I-487,




I-491,




I-492,




I-495,




I-497,




I-501,




I-502,




I-512,




I-593,




I-594,




I-595,




I-596,




I-599,




I-605,




I-606,




I-611,




I-626,



I-652,



I-662,



I-663 y sales

aceptables desde un punto de vista farmacéutico, hidratos, polimorfos, cocristales, tautómeros, estereoisómeros o derivados marcados con isótopos de estos.

23. Una composición farmacéutica que comprende un compuesto de cualquiera de las Reivindicaciones 1-22, o una sal aceptable desde un punto de vista farmacéutico, solvato, hidrato, polimorfo, cocrystal, tautómero, estereoisómero o derivado marcado con isótopos de estos, y opcionalmente un excipiente aceptable desde un punto de vista farmacéutico;

opcionalmente, en la que la composición comprende además un agente farmacéutico adicional;

además opcionalmente, en la que el agente farmacéutico adicional es un agente quimioterapéutico o un agente de diferenciación.